Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer
| Class:Id | LiteratureReference:9679427 |
|---|---|
| _displayName | Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer |
| _timestamp | 2020-03-24 15:56:40 |
| author | [Person:9679422] Kline, Justin [Person:9679410] Gajewski, Thomas F |
| created | [InstanceEdit:9679442] Jassal, Bijay, 2020-03-24 |
| journal | Curr Opin Investig Drugs |
| pages | 1354-9 |
| pubMedIdentifier | 21154117 |
| title | Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer |
| volume | 11 |
| year | 2010 |
| (literatureReference) | [Reaction:9679421] PDCD1 binds PDCD1 inhibitors [Homo sapiens] [RegulationReference:9690985] Negative regulation by 'PDCD1:PDCD1 inhibitors [plasma membrane]' Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer (9679427)
